Trial Profile
A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Asian Subjects With Active Rheumatoid Arthritis Having Previously Failed TNF Blocker Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Olokizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors UCB; UCB Japan
- 02 Nov 2016 Pooled analysis of patient-reported outcomes of 4 trials, (NCT01242488, NCT01463059, NCT01296711 and NCT01533714) were presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov (parent trial) record.